| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CFB |
| Uniprot No | P04186 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 23-761aa |
| 氨基酸序列 | TPVLEARPQVSCSLEGVEIKGGSFQLLQGGQALEYLCPSGFYPYPVQTRTCRSTGSWSDLQTRDQKIVQKAECRAIRCPRPQDFENGEFWPRSPFYNLSDQISFQCYDGYVLRGSANRTCQENGRWDGQTAICDDGAGYCPNPGIPIGTRKVGSQYRLEDIVTYHCSRGLVLRGSQKRKCQEGGSWSGTEPSCQDSFMYDSPQEVAEAFLSSLTETIEGADAEDGHSPGEQQKRKIVLDPSGSMNIYLVLDGSDSIGSSNFTGAKRCLTNLIEKVASYGVRPRYGLLTYATVPKVLVRVSDERSSDADWVTEKLNQISYEDHKLKSGTNTKRALQAVYSMMSWAGDAPPEGWNRTRHVIIIMTDGLHNMGGNPVTVIQDIRALLDIGRDPKNPREDYLDVYVFGVGPLVDSVNINALASKKDNEHHVFKVKDMEDLENVFYQMIDETKSLSLCGMVWEHKKGNDYHKQPWQAKISVTRPLKGHETCMGAVVSEYFVLTAAHCFMVDDQKHSIKVSVGGQRRDLEIEEVLFHPKYNINGKKAEGIPEFYDYDVALVKLKNKLKYGQTLRPICLPCTEGTTRALRLPQTATCKQHKEQLLPVKDVKALFVSEQGKSLTRKEVYIKNGDKKASCERDATKAQGYEKVKDASEVVTPRFLCTGGVDPYADPNTCKGDSGGPLIVHKRSRFIQVGVISWGVVDVCRDQRRQQLVPSYARDFHINLFQVLPWLKDKLKDEDLGFL |
| 预测分子量 | 85.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与CFB(补体因子B，Complement Factor B)重组蛋白相关的参考文献及简要摘要：
---
1. **文献名称**：*Structural Basis of Complement Factor B Regulatory Activation in the Alternative Pathway*
**作者**：Forneris F, et al.
**摘要**：该研究通过X射线晶体学解析了人源补体因子B(CFB)的活化结构，揭示了其与补体C3b结合后的构象变化机制，阐明了CFB在补体替代途径中的关键调控作用。
---
2. **文献名称**：*Recombinant Human Factor B: Functional Characterization in Complement Activation and Disease Models*
**作者**：Schmidt CQ, et al.
**摘要**：本文报道了通过哺乳动物细胞系统表达重组人CFB，并验证其在体外补体激活中的功能，进一步在补体介导的肾小球肾炎模型中证明其病理作用，为靶向治疗提供依据。
---
3. **文献名称**：*Expression and Purification of Active Recombinant Complement Factor B in Escherichia coli*
**作者**：Zhang S, et al.
**摘要**：研究成功在大肠杆菌中表达可溶性重组CFB蛋白，通过优化表达条件和亲和层析纯化获得高活性蛋白，为低成本生产CFB用于功能研究和药物筛选奠定基础。
---
**备注**：以上文献为示例性质，实际引用时需核实最新研究或具体数据库(如PubMed)中的论文。若需要更近期文献，建议补充关键词如“recombinant CFB”或“complement factor B therapy”进一步检索。
**Background of CFB Recombinant Proteins**
Complement Factor B (CFB) is a critical serine protease in the complement system, a key component of innate immunity. It plays a central role in the alternative pathway of complement activation, where it binds to C3b to form the C3bB complex. This complex is cleaved by factor D into Bb and Ba fragments, generating the C3 convertase (C3bBb), which amplifies the complement cascade, leading to pathogen opsonization, inflammation, and cell lysis. Dysregulation of CFB is linked to autoimmune diseases, age-related macular degeneration (AMD), and inflammatory disorders.
Recombinant CFB proteins are engineered using biotechnological methods, such as expression in mammalian (e.g., HEK293. CHO cells) or bacterial systems, to produce purified, functional CFB for research and therapeutic applications. These proteins retain the biological activity of native CFB, enabling studies on complement pathway mechanisms, drug screening, and disease modeling.
The development of CFB recombinant proteins has been driven by the need to target the complement system therapeutically. Inhibitors or modulators of CFB are being explored to treat complement-mediated diseases. For example, monoclonal antibodies or small molecules targeting CFB or its active site could suppress overactivation in conditions like paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome (aHUS).
Additionally, recombinant CFB serves as a tool to standardize diagnostic assays, quantify CFB levels in clinical samples, and evaluate genetic mutations affecting complement function. Advances in protein engineering, such as site-specific mutagenesis or glycoengineering, further optimize recombinant CFB stability, activity, and compatibility with human physiology.
Overall, CFB recombinant proteins bridge basic research and clinical innovation, offering insights into complement biology and paving the way for novel therapies targeting immune dysregulation.
×
